Articles On Patrys (ASX:PAB)
Title | Source | Codes | Date |
---|---|---|---|
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | PAB | 1 week ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | PAB | 2 weeks ago |
Closing Bell: ASX gains as lithium, iron ore miners dazzle; copper and gold stocks extend rally
The ASX200 closed +0.5% higher on Tuesday on the back of a big lift in the Mining sector. Lithium stocks led, with IGO (ASX:IGO) and Pilbara (ASX:PLS) gaining around 3%. Iron ore miners rallied after the Nymex CFR China, 62% Fe price swu... |
Stockhead | PAB | 1 month ago |
Patrys releases positive data from deoxymabs study to treat ANCA vasculitis
Patrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. The therapeutic antibody developme... |
smallcapsau.mystagingwebsite.com | PAB | 1 month ago |
ASX Health Stocks: Patrys and Next Science jump after presenting data on studies
Patrys’ deoxymabs data on vasculitis disease presented Next Science’s BLASTX data published Patrys’ deoxymabs data presented Patrys (ASX:PAB) jumped 12% this morning after announcing that new data from preclinical studies using PAT-DX1... |
Stockhead | PAB | 1 month ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | PAB | 2 months ago |
Closing Bell: Buyers ambush benchmark setting new benchmark
Local markets started slow before ripping into an all-time intraday high 10 of 11 sectors higher, benchmark closes 0.50pc up Small Caps led by Motio, Cue Energy and Sierra Rutile Some strong earnings on the last day of February and... |
Stockhead | PAB | 2 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | PAB | 2 months ago |
10 at 11ish: Aurumin to sell iron rights to Mineral Resources
Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by... |
Stockhead | PAB | 5 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | PAB | 5 months ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | PAB | 6 months ago |
Closing Bell: Local markets end 0.4pc higher led by big banks and a few small biotechs
Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix The ASX200 is up +0.4% at the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l... |
Stockhead | PAB | 7 months ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | PAB | 7 months ago |
ASX cancer stocks guide: Here’s everything you need to know
According to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO defines cancer as a generic term for a large group of diseases that can affect any part of the body with malignant tumours and neoplasms. W... |
Stockhead | PAB | 7 months ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | PAB | 7 months ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | PAB | 8 months ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | PAB | 8 months ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | PAB | 9 months ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | PAB | 10 months ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | PAB | 11 months ago |
CLOSING BELL: Someone please give the market a nudge… I think it’s fallen asleep
The ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Times among the lithium players, it’s been a total snoozefest Rubix Resources (ASX:RB6) takes bragging rights with a 41.6% hike for the day ... |
Stockhead | PAB | 11 months ago |
In Case You Missed It: Lithium takes the lead, followed by biotech and manganese today
Stockhead’s In-Case-You-Missed-It highlights some of the strongest-performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag... |
Stockhead | PAB | 11 months ago |
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
Patry receives positive toxicology reports on PAT-DX1 Immutep says triple combination trial of Efti shows it is well tolerated Clarity Pharma is now advancing to cohort 2 Patrys receives positive report Therapeutic antibody development... |
Stockhead | PAB | 11 months ago |
Top 10 at 10: These ASX lithium, gas and biotech stocks are Hump Day heroes
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | PAB | 11 months ago |
CLOSING BELL: A crazy ride for tech stocks and Wildcat as the ASX dips 0.22%
ASX sinks to -0.4% before slogging its way back to -0.22% for the day. Tech stocks were all over the shop but came out on top with +1.2%. Wildcat (ASX:WC8) was King of the Small Caps, adding 34.5% on no fresh news. After sinking as low... |
Stockhead | PAB | 11 months ago |
CLOSING BELL: The ASX dips while we ‘hurry up and wait’ to see what The Budget holds
ASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today, adding 0.5% on an otherwise fairly moribund day Voltaic Strategic Resources climbs 188% on pre-assay lithium results at Ti Tree The ASX h... |
Stockhead | PAB | 1 year ago |
ASX April Winners: Mid and small caps outperform blue-chip peers as gold stocks keep up rally
The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru... |
Stockhead | PAB | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | PAB | 1 year ago |
Top 10 at 10: ASX minnow celebrates oil production milestone, another unveils high grade gold stash
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | PAB | 1 year ago |
Market Close: ASX breaks seven-week losing streak
Stable commodity prices and mining stocks saw the ASX break its seven-week losing streak. The ASX 200 is up 2 per cent this year so far after adding 55 points today. All but one of the 11 sectors were in the green, with materials lead... |
themarketherald.com.au | PAB | 1 year ago |
CLOSING BELL: ASX closes higher to end week, materials leading bourse upwards
ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So... |
Stockhead | PAB | 1 year ago |
TMH Spotlight: Nova Eye Medical (ASX:EYE) gets FDA greenlight, EML Payments (ASX:EML) sinks on bank growth cap
As the first quarter of this calendar year wraps up, Sayona Mining (SYA) and Piedmont Lithium (PLL) have restarted the North American lithium project in Quebec, Canada. Re-start operations were first announced in 2021 and since then, the... |
themarketherald.com.au | PAB | 1 year ago |
Patrys (ASX:PAB) shares tumble as PAT-DX1 cancer treatment trial gets pushed back
Patrys (PAB) shares are slumping on Friday after the company flagged delays over the phase one clinical trial of its PAT-DX1 compound PAB CEO and Managing Director James Campbell says it is “disappointing” to push back the trial for its... |
themarketherald.com.au | PAB | 1 year ago |
Top 10 at 10: These ASX fintech, biotech and gold stocks are flying on Friday
Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | PAB | 1 year ago |
Patrys' says preclinical data supports synthetic lethality mechanism
Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic le... |
BiotechDispatch | PAB | 1 year ago |
ASX falls 1.4% to three-month low
ShareCafeASX falls 1.4% to three-month low by Peter Milios At the closing bell, the S&P/ASX 200 was 1.4 per cent lower at 7,008.9, a three-month low. The fall was mainly due to concerns about a financial crisis after the collapse of U... |
ShareCafe | PAB | 1 year ago |
Patrys (ASX:PAB) flags “synthetic lethality” potential of PAT-DX3 cancer treatment
Patrys (PAB) claims a recent pre-clinical study of its PAT-DX3 drug shows the product could treat cancer through “synthetic lethality” strategies The company says its drug platform is designed to cause DNA damage to certain tumours to ul... |
themarketherald.com.au | PAB | 1 year ago |
ASX down 1.91% at noon to lowest point since Jan
ShareCafeASX down 1.91% at noon to lowest point since Jan by Peter Milios Earlier today, the S&P/ASX 200 stock index of Australia experienced a decline of 2.1 per cent and hit a new low of 6956.7, which is close to its lowest point of... |
ShareCafe | PAB | 1 year ago |
Stocks of the Hour: Patrys, Mt Monger Resources, Immutep
14 Mar 2023 - A snapshot of the stocks on the move featuring Patrys (ASX:PAB), Mt Monger Resources (ASX:MTM) and Immutep (ASX:IMM). |
FNN | PAB | 1 year ago |
Stocks of the Hour: PAB, MTM, IMM
ShareCafeStocks of the Hour: PAB, MTM, IMM Patrys (ASX:PAB) has announced that their preclinical data supports synthetic lethality mechanisms to treat relevant cancers. Patrys Chief Executive Officer and Managing Di... |
ShareCafe | PAB | 1 year ago |
ASX Health Stocks: Patrys’ drug exhibits cancer lethality, US Patent Office says yes to Alterity
Patrys says pre-clinical data supports its drug’s synthetic lethality mechanism Alterity granted patent in the US Optiscan says 100% of cancer cases were diagnosed correctly using its device Patrys’ PAT-DX3 shown to have ‘synthetic leth... |
Stockhead | PAB | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | PAB | 1 year ago |
Patrys (ASX:PAB) receives $3.35m R&D tax incentive refund
Patrys (PAB) subsidiary Nucleus Therapeutics receives a $3.35 million research and development tax incentive refund from the Australian Federal Government The funds are for R&D undertaken during the 2021/2022 financial year Patrys... |
themarketherald.com.au | PAB | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | PAB | 1 year ago |
Closing Bell: This year’s Christmas hangover, brought to you by rising interest rates
Both the ASX 200 and small cap index were in the green today A massive 11 out 11 sectors finished higher let by Utilities Westpac says rising interest rates and cost of living will hit consumers and businesses after Xmas The ASX 200 was... |
Stockhead | PAB | 1 year ago |
Webinar Recap – HPC, PAB, MKR & SRR
ShareCafeWebinar Recap – HPC, PAB, MKR & SRR Catch up on the full presentations form the Hydration Pharmaceutical Company (ASX: HPC), Patrys (ASX: PAB), Manuka Resources (ASX: MKR) & Sarama Resources (ASX: SRR) – Webinar presentati... |
ShareCafe | PAB | 1 year ago |
Patrys (ASX: PAB) – Webinar presentation
ShareCafePatrys (ASX: PAB) – Webinar presentation James Campbell – Managing Director & CEO Patrys is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. Patr... |
ShareCafe | PAB | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | PAB | 1 year ago |
BRIEF-Patrys Appoints Charmaine Gittleson As Chairman
Nov 16 (Reuters) - Patrys Ltd: * PATRYS APPOINTS DR CHARMAINE GITTLESON AS CHAIRMAN Source text for Eikon: Further company coverage: |
Kalkine Media | PAB | 1 year ago |
Patrys (ASX:PAB) confirms PAT-DX3 crosses blood-brain barrier in healthy animals
Patrys (PAB) confirms its PAT-DX3 antibody can cross the blood-brain barrier in healthy animals after receiving new preclinical data for the productA new PAT-DX3 study found the uptake into the brain of the product, per cubic centimetre, wa... |
themarketherald.com.au | PAB | 1 year ago |